In LATTICE-UC (NCT03934216), no significant differences in week 12 clinical remission (primary endpoint) and endoscopic response rates were seen compared to placebo (NCT04877990).115 However, other TYK2 inhibitors are still under investigation in IBD. This evidence concerns the gene TYK2 and inflammatory bowel disease.